Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 2

Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada) General Information

Description

Commercial rights of the ATX-101. The asset includes all rights outside of the U.S. and Canada to ATX-101, a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Primary Office
  • 51368 Leverkusen
  • Germany
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada)‘s full profile, request access.

Request a free trial

Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bayer Consumer Care (Rights to ATX-101 Outside of the US and Canada)‘s full profile, request access.

Request a free trial